Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, you're wrong. There will be NO UPDATE on the Agenda Clinical trial, period.
No, I would say that people are selling their shares below the ask price.
People need to realize that a buy is a sell. It's a market. There is a buyer and there is a seller.
Unless there is dilution.
Real simple. If someone is buying a stock then someone is selling it, sir. That is, unless, there is dilution.
When it was moving up, or when it was selling off...or both?
That's a little premature.
You have yet to bring any facts or DD to this community. You don't know anything about this stock. Nothing released today wasn't something that wasn't already known.
I certainly would, especially if it went up on a reminder PR that offered nothing new. That's just dumb luck in other stocks, but not in GNTA land. A reminder PR sends this security up big.
It's clearly a good idea with GNTA...
...because the company can simply send out a reminder that they're presenting at a conference, with no new information or analytical data, and the stock can shoot up 33%.
Nice trade, cordog.
I agree...
...veterans and knowledgeable people holding Genta shares are robbing newbies blind right now.
Zero new information.
Caught wind of what?
Old news?
It says nothing of the sort...
...this is the exact kind of news that newbies will bite on. It is saying absolutely nothing new whatsoever. Everyone knew they'd be presenting at this conference.
AGENDA results will NOT be released because they don't have them and Tesetaxel hasn't even been granted an SPA yet from the FDA to start a clinical study, so you know there's no new data there.
They're simply reminding folks that they'll be presenting.
BFD.
Today's PR
...it doesn't look like they are presenting any new data. Nothing with respect to the AGENDA trial. Just old stuff they've presented 1,000 times before.
I wonder if they'll present on their plans for a reverse split.
Don't be so sure, Genta has 6 BILLION shares authorized.
Dilution and selling.
Ice cold
...Dilution.
This has absolutely NOTHING to do with Genta.
It doesn't, read this snippet for insight into the truth.
Recent 8-K filed pretty much confirms a R/S as a stipulation, that is unless they don't want the money (the other half of the "up to 12MM in financing").
"The 2009 Notes include certain events of default, including a requirement that the Company effect a reverse stock split of the Company’s Common Stock within 105 days of the Initial Closing. There are currently not enough shares of common stock authorized under the Company’s certificate of incorporation to cover the shares underlying the 2009 Notes."
Preliminary results won't be ready for 6 months at the earliest. They will have to reverse split by that time.
Partnerships are always a possibility...
...but I believe potential partnership suitors are likely VERY put off by the way Aventis pulled out of the partnership with Genta, leaving them high and dry, and yanking the submitted NDA off the table from the FDA.
Aventis partnered with Genta on Genasense...it didn't end well.
No, no, no...don't misunderstand what I said.
I said that the first analytical results from the trial won't be available for at least 6 months. That's the first step.
The NDA submission won't be able to happen until some time after that data has been fully captured, analyzed, and packaged. Genta leadership penciled in the NDA submission for the end of 2009, December. A question was asked in the conference call if Genta would submit on a rolling basis and the CEO said that while that was a possibility, they would not do such a thing.
It will take even longer for an FDA response after the NDA submission. You're looking mid to late 2010 for an approvable/denial response from the FDA and EMEA.
Let me just say this, prsch3259...
...for what it's worth; you, sir, have my respect.
I think you are very much like me, sans one thing...I don't own shares. I do, however, have a strong interest in Genta and its pipeline. I would like to hold shares, but not with everything on the horizon for the company short-term, with respect to its financial situation.
I find myself oft in agreement with your assessments.
Good luck to you.
Nice painted close.
The EMEA can't approve the drug...
...until the trial is complete and shows significant confirmatory evidence of the 1st trial results in participants with normal to low LDH values.
Those data will not be available until 6 months from now at the earliest. Genta will have to reverse split before that timeframe.
Sorry, don't be mislead by others who will capitalize on those who haven't done research on the subject.
Then you, and others, need to do more research.
This is the problem and why so many will lose money here. They aren't willing to put in the time to understand what they're getting into.
The pps will be much higher than .02
...but the intrinsic value will be worth nothing. Why? The reverse split and dilution.
The Agenda Trial...
...is designed to meet EMEA expectations of a confirmatory trial in the treatment of melanoma as well. There is no separate study solely for Europe.
The answer is no.
Incorrect, again.
If they don't impose the reverse split withing 105 days from the initial closing for the 1st half of 12MM in financing, they won't receive the other half.
Read the filing.
Why buy when you can wait for the reverse split and dilution that will follow? There's nothing on the horizon, realistically, to make this attractive to anyone right now. Let them go through their financial motions with your money on the sidelines.
I'm assuming...
...this applies to posters who have a glass half full and a glass half empty perspective, correct?
I've never seen anyone on this message board say that this "wasn't a real company" or that it was a "scam".
On the contrary. It's a very real company, with two very interesting and innovative drugs, in very real financial distress.
I know who...
...represents the big money and you're not one of them. So quit acting like you know something or are a part of something. You don't and you're not.
Why do you say that? Gold why?
Right, but why should any smart investor keep their money in a company who plans to dilute, reverse split, etc. when a decision on their bread and butter drug is still more than a year away?
No one is arguing whether or not the drugs are exciting. The problem is all of the financial hurdles the company will have to clear at the expense of the shareholders to get them to market.
20 years of FDA denials can turn suitors off.
Good luck.
If shareholders don't vote in favor of the reverse split, it won't matter. Genta won't have any other choice but to reverse split if they want money to continue operations. Basically, if shareholders vote "No" to the reverse split, they'll be voting to shut the company down.
They will have to continue to issue shares if they want to get paid. There have no other source of income and they are operating on a $2MM/month burn rate.
You haven't even SEEN the dilution that's going to come after the reverse split.
No, not if they don't want the other half of the 12 million in financing. At least that's the way I understand it.